Építés alatt – nem éles oldal
Belépés
Befejeződött3. fázis

ALBumin Italian Outcome Septic Shock-BALANCED Trial (ALBIOSS-BALANCED)

A legfontosabb adatok

Ki végzi
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Hol
Olaszország37 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Fázis
3. fázis
Résztvevők
1319 fő vett részt
Kezdés
2019. máj. 7.
Befejezés
2025. jan. 31.
A vizsgálat típusa
Beavatkozással járó, 4 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
A vizsgált kezelések
  • Albumin
  • Balanced
A regiszteradat frissítve
2025. március 5.

Ki vehet részt

Életkor
18 év – 100 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 16 feltétel megnézéseKevesebb

Ki vehet részt

  • Patients with septic shock if they meet the two following criteria:
  • Presence of an infection (known or suspected) in at least one site:; Lung; Abdomen; Urinary tract; Others (blood, skin and soft tissues, central nervous system, bones and joints, cardiac system, reproductive organs)
  • Presence of a severe and acute, sepsis-related cardiovascular failure (as assessed by the SOFA score - see Annex 1), requiring vasopressor to maintain mean arterial pressure >=65 mmHg, despite adequate volume resuscitation a) Cardiovascular SOFA score > 2 (3 or 4) If the patient is unable to provide informed consent, she/he can be included in the trial provided that the requirements of ongoing laws are fulfilled; details on this approach are provided in the protocol, par 11.1 and related Annex 3. The patient will be informed about having been included in a clinical trial, as soon as she/he will regain consciousness

Ki nem vehet részt

  • Severe congestive heart failure (NYHA III and IV classes)
  • Presence of chronic end-stage renal disease
  • Known or suspected adverse reaction to albumin administration
  • Clinical situations in which the use of albumin is known or supposed to be clinically beneficial (hepatic cirrhosis with ascites, malabsorption syndrome or protein-losing enteropathy, nephrotic syndrome, burns)
  • Severe hyperkalemia (> 6 mmol/L)
  • Laboratory confirmation for SARS-CoV-2 infection
  • Age < 18 years
  • Moribund state
  • Septic shock in patients with traumatic brain injury or a clinically active cerebral lesion (known or suspected)
  • More than 24 hours after the onset of septic shock
  • Religious objection to the administration of human blood products
  • Known or suspected pregnancy based on patient information
  • Enrollment in other experimental interventional studies

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Septic shock is a devastating condition often observed in ICU. It is characterized by pro-inflammatory and immune responses, organ failures, high incidence of AKI and lethality. Fluid resuscitation is pivotal as supportive therapy. At present, there are no effective therapies to improve survival of such clinical condition, often characterized by a mortality as high as 40% during the first 90 days from diagnosis.

A teljes eredeti leírásKevesebb

This project proposes a large 2-by-2 factorial randomized clinical trial testing the efficacy of albumin and the low- chloride balanced crystalloid solutions (either Ringer Lactate, Ringer Acetate, or Crystalsol - BAL) in septic shock.

The investigators have recently concluded a multicenter, randomized trial, the ALBIOS trial, in which, in a post-hoc analysis, albumin, in addition to crystalloids, reduced 90-day mortality in patients with septic shock, as compared to crystalloids alone (Caironi P et al, 2014). Crystalloids with supra-physiological chloride content may deteriorate renal perfusion, increasing the risk of acute kidney injury (AKI) and mortality.

A vizsgálat 4 csoportja

  • Albumin + BalancedA vizsgált kezelés

    Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination. Balanced crystalloid solutions According to the preference and the standard use of the participating center: * Ringer Lactate * Ringer Acetate * Crystalsol

    Kezelés: Albumin és Balanced

  • Albumin + SalineA vizsgált kezelés

    Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination. Normal Saline Na+ 154 mEq/L, Cl- 154 mEq/L (0.9% NaCl).

    Kezelés: Albumin

  • BalancedA vizsgált kezelés

    Balanced crystalloid solutions (Ringer Lactate, Ringer Acetate, Crystalsol)

  • SalineNincs vizsgálati kezelés, összehasonlításként

    Normal Saline Na+ 154 mEq/L, Cl- 154 mEq/L (0.9% NaCl).

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Efficacy of Albumin Replacement and Balanced Solution in Patients With Septic Shock (the ALBIOSS-BALANCED Trial): a 2-by-2 Factorial, Investigator-initiated, Open- Label, Multicenter, Randomized, Controlled Trial
A regiszteradat frissítve
2025. március 5.